News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Solasia Pharma K.K. Announces Initiation of Darinaparsin Injection (SP-02) Phase 1 Study


10/26/2011 8:13:39 AM

TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (Minato-ku, Tokyo) announced today that enrollment of a Phase I clinical trial evaluating the safety and tolerability of darinaparsin injection (SP-02L) for the treatment of peripheral T-cell lymphoma (PTCL), has commenced in Japan. Darinaparsin is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid cancers. In several studies conducted in the US and other countries, darinaparsin injection has demonstrated good tolerability and safety. In addition, a Phase II study of darinaparsin injection in the US, demonstrated clinical responses in lymphoma, in particular PTCL.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES